SCHEMBL3774486

SCHEMBL3774486

COc1ccc(-c2ccc(N3CCN(CC(=O)N4CCN(C5CCC5)CC4)CC3)cc2)cc1F

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.46
MAPT P10636 4/20 0.46
CYP1A2 P05177 1/20 0.46
CYP3A4 P08684 1/20 0.46
CYP2D6 P10635 1/20 0.46
CYP2C19 P33261 1/20 0.46
MAPK1 P28482 3/20 0.45
TDP1 Q9NUW8 2/20 0.45
RAB9A P51151 1/20 0.45
ALOX15 P16050 1/20 0.44
HSD17B10 Q99714 1/20 0.44
HPGD P15428 1/20 0.44
KDM4E B2RXH2 2/20 0.43
TLR8 Q9NR97 1/20 0.43
TLR7 Q9NYK1 1/20 0.43
LMNA P02545 3/20 0.43
HRH3 Q9Y5N1 1/20 0.43
GFER P55789 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
MEN1 O00255 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3771815 0.92 TSHR (0.45) ALDH1A1MAPTMAPK1TDP1RAB9A
SCHEMBL3773763 0.92 HSD17B10 (0.53) ALDH1A1MAPTCYP1A2CYP3A4CYP2D6
SCHEMBL3765482 0.90 HSD17B10 (0.45) ALDH1A1MAPTCYP1A2CYP3A4CYP2D6
SCHEMBL3773827 0.89 ALDH1A1 (0.44) ALDH1A1MAPTCYP1A2CYP3A4CYP2D6
SCHEMBL3772005 0.88 GFER (0.50) ALDH1A1MAPTCYP1A2CYP3A4CYP2D6
SCHEMBL3773892 0.88 LMNA (0.47) ALDH1A1MAPTMAPK1TDP1RAB9A
SCHEMBL3769379 0.87 ALDH1A1 (0.48) ALDH1A1MAPTCYP1A2CYP3A4CYP2D6
SCHEMBL3761169 0.87 ACVR1 (0.46) ALDH1A1MAPTMAPK1TDP1RAB9A
SCHEMBL3768088 0.86 GFER (0.47) ALDH1A1MAPTCYP2C19MAPK1KDM4E
SCHEMBL3773986 0.86 GFER (0.50) ALDH1A1MAPTMAPK1KDM4ELMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 US disclosed
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 US disclosed
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 US disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 US disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 US disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 US disclosed
WO-2007016496-A2 DIPIPERAZINYL KETONES AND RELATED ANALOGUES NEUROGEN CORPORATION (US) 2007-02-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070049571-A1 Dipiperazinyl ketones and related analogues HRH4, HRH3, HRH1 ALDH1A1 1210/4885MAPT 1475/4885CYP1A2 1775/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.